Sun Pharmaceutical Industries Limited is one of India’s largest pharmaceutical companies. It is known for producing high-quality generic medicines and specialty drugs for various therapeutic areas.
Sun Pharma Share Price Target 2025
About Sun Pharma
Sun Pharma is a leading global pharmaceutical company that provides medicines in over 100 countries. It has a strong presence in India, the US, and emerging markets with a focus on dermatology, ophthalmology, and chronic disease treatments.
Company Details
Founded: 1983
Headquarters: Mumbai, India
Industry: Pharmaceuticals, Healthcare
Market Cap: Over INR 3 lakh crore (as of 2024)
Key Focus Areas: Specialty medicines, generics, active pharmaceutical ingredients (APIs)
Promoter
Name
Stake Percentage
Dilip Shanghvi & Family
54.48%
Public & Others
45.52%
Sun Pharma Share Price Target 2025
Maximum Target: INR 1,700
Minimum Target: INR 1,400
Sun Pharma is expected to perform well in 2025 due to its expanding specialty drug portfolio, strong US market presence, and increasing global demand for generics. The company continues to invest in R&D and acquisitions to drive growth.
Factors Affecting Sun Pharma Share Price in 2025:
Strong Global Presence: Expanding in the US and emerging markets.
R&D Investments: Innovation in specialty drugs and biosimilars.
Regulatory Approvals: Key drug launches in major markets.
Revenue Growth: Strong financials and increasing sales.
Partnerships & Acquisitions: Expanding product portfolio through strategic deals.
FAQs About Sun Pharma
Is Sun Pharma a good stock for 2025?
Yes, with a strong global footprint, consistent revenue growth, and a focus on specialty medicines, Sun Pharma remains a solid investment option.
What are Sun Pharma’s key business segments?
The company operates in branded generics, US generics, specialty drugs, and APIs.
I a finance writer with 2+Year of Exp in financial topics. With BBA in Finance degree, content writer, SEBI-certified investor, and stock market enthusiast.
Recent Posts
Infosys Q4 results schedule out: Check date, timing, & other details - Upstox
Wendt (India) Limited Schedules Board Meeting for April 24, 2026 to Approve FY26 Results and Final Dividend - scanx.trade
Wipro Q4 results: IT stock in focus ahead of quarterly results, buyback announcement - India TV News
Indian Stocks Climb on Peace Hopes; Wipro, HDB Financial Results in Focus - Whalesbook
Dividend, Share Buyback in Q4 results 2026: Double delight by THIS BSE 500 stock; board meeting next week - ET Now
Indian Financial Firms: Results, Dividends Due Amid HDFC Bank Shake-up, Bajaj Acquisition - Whalesbook
Q4 result today: ICICI Prudential, Den Networks among 8 firms on April 14 - Business Standard
Anand Rathi, ICICI Prudential Life Insurance and 5 other stocks announcing Q4 results today - Trade Brains
Patanjali Foods board to meet on April 21 to consider second interim dividend, Q4 earnings - The Economic Times
India Pesticides Corrects XBRL Error in Quarterly Results Filing - TipRanks
Q4 results 2026: Wipro, HDFC Bank, ICICI Bank among 50 companies to declare earnings next week; check full list here - Mint
D-Street week ahead: Q4 earnings, Iran-US talks outcome to drive markets in truncated trading week - The Economic Times